Donor-specific antibodies have become an established biomarker predicting antibody-
mediated rejection. Antibody-mediated rejection is the leading cause of graft loss after …

The human major histocompatibility complex is a family of genes that encodes HLAs, which
have a crucial role in defence against foreign pathogens and immune surveillance of …

Despite the success of desensitization protocols, antibody-mediated rejection (AMR)
remains a significant contributor to renal allograft failure in patients with donor-specific …

Sensitization, defined as the presence of circulating antibodies, presents challenges for
heart transplant recipients and physicians. When present, sensitization can limit a …

For patients with ESRD, kidney transplant offers significant survival and quality-of-life
advantages compared with dialysis. But for patients seeking transplant who are highly …

Previous evidence suggests that a homeostatic germinal center (GC) response may limit
bortezomib desensitization therapy. We evaluated the combination of costimulation …

We present this observational study of lung transplant recipients (LTR) treated with
carfilzomib (CFZ)-based therapy for antibody-mediated rejection (AMR) of the lung. Patients …

Remarkable advances have been made in the pathophysiology, diagnosis, and treatment of
antibody-mediated rejection (ABMR) over the past decades, leading to improved graft …

Heart transplantation (HT) remains the preferred therapy for patients with advanced heart
failure. However, for sensitized HT candidates who have antibodies to human leukocyte …

The engraftment failure associated with Abs to donor-specific HLA (DSA) limits options for
sensitized BMT candidates. Fourteen of fifteen patients with no other viable donor options …